From a glucose perspective, insulin therapy in T2DM is therefore aimed at preventing excessive gluconeogenesis, that is, fasting hyperglycaemia with basal insulin and short (or ultra-short) acting insulin to limit the degree of postprandial glucose increases.23 Here, INS is linked to type 2 diabetes mellitus.